Scrip
Nycomed fights pantoprazole loss to post growth
16 November 2009
Christopher Spillane
Please Login to read the full article.
16 November 2009
Christopher Spillane
christopher.spillane@informausa.com
Nycomed's third-quarter net turnover crept up by almost 1% to €820 million despite losing patent exclusivity for its biggest selling product, pantoprazole (Protonix). Gross profits were also up, rising by 1% to €597 million.
Revenues for the gastro-oesophageal reflux disease (GORD)...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Pantoprazole produces mixed results for Nycomed
- US jury verdict on validity of Pfizer's Protonix patent puts at-risk launches in spotlight
- Alarming rise in chronic use of meds by American children, Medco report says
- 2009 results preview: big pharma grapples to varying degrees of success with generic erosion
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
